Research Funded

Overcoming fusion oncoprotein dependence through CIC-DUX4 target gene inhibition in undifferentiated sarcoma

Ross Okimoto, MD, University of California, San Francisco
Recipient of the: $50,000 Sarcoma Foundation of America Research Award

Abstract: The CIC-DUX4 fusion oncoprotein is an understudied molecular entity that characterizes a rare but lethal subset of undifferentiated round cell sarcomas. CIC-DUX4 patients have dismal clinical outcomes due to 1) an incomple... Read More

Redirecting B7H3 CAR T cells To Sarcoma using Midkine Receptors

Jessica Lake, MD, University of Colorado
Recipient of the: $50,000 Sarcoma Foundation of America Research Award

Abstract: Advances in pediatric oncology have occurred for some cancers, however, new therapies for sarcoma (osteosarcoma and rhabdomyosarcoma) have been sparse. The 5-year disease-free survival is 20-30% for patients with metastati... Read More

Function and targeting of a 5hmC-methylosome complex in synovial sarcoma

Le Su, PhD, HudsonAlpha Institute for Biotechnology
Recipient of the: $50,000 Sarcoma Foundation of America Research Award

Abstract: Synovial sarcoma is a deadly form of malignant soft tissue tumors, most commonly affecting children and young adults. Approximately all the patients bear a pathognomonic chromosomal translocation, t(X;18), which fuses the ... Read More

Uncover principles underlying cryoablation-induced immunotherapy effects in sarcomas

Alex Huang, MD, PhD, Case Western Reserve University
Recipient of the: $50,000 Sarcoma Foundation of America Research Award

Abstract: Malignant sarcomas comprise 12% of all pediatric cancers. Despite its rare occurrence, sarcomas are life threatening and difficult to treat, and nearly half of all patients will have recurrence and metastasis.  The two mo... Read More

Characterising the Proteomic Landscape of Angiosarcomas

Paul Huang, PhD, Royal Marsden Hospital
Recipient of the: $50,000 Sarcoma Foundation of America Research Award

Abstract: Angiosarcoma (AS) is an aggressive disease that accounts for 2-3% of soft tissue sarcomas (STS). The long-term outlook of patients with incurable advanced or metastatic disease is poor, with a median overall survival of le... Read More

A novel precision medicine approach to treat advanced liposarcoma

Harri Sihto, PhD, University of Helsinki
Recipient of the: $50,000 Florence & Marshall Schwid Memorial Research Award

Abstract: Liposarcomas (LPSs) are heterogenous group of soft-tissue sarcomas, which outcome depends strongly on the site of the primary tumor and tumor histotype. At the moment, there are not available any efficacious targeted thera... Read More

Dissecting the contribution of germline genetics to pediatric sarcoma pathogenesis

Riaz Gillani, MD, Dana-Farber Cancer Institute
Recipient of the: $50,000 Jay Vernon Jackson Memorial Research Award

Abstract: Amongst pediatric cancers, bone and soft tissue sarcomas are often associated with the poorest prognoses and most limited effective treatment options. Understanding the genetics that predispose to the development of childh... Read More

Endoglin CAR T cells for Immunotherapy of Ewing Sarcoma

Sujith Kurian Joseph, PhD, Baylor College of Medicine
Recipient of the: $50,000 Pittsburgh Cure Sarcoma/Giving Tuesday Research Award

Abstract: Ewing sarcoma is the second common bone cancer in children and young adults. It is an aggressive type of cancer that spreads rapidly to other organs in the body. Ewing sarcoma that recurs or that has spread to other parts ... Read More

Multi-faceted immunostimulatory therapy for Ewing Sarcoma (MITES)

Margaret Chou, PhD, Children's Hospital of Philadelphia
Recipient of the: $50,000 The Philadelphia Flyers Community Research Award Honoring Oskar Lindblom

Abstract: Ewing sarcoma (ES) is the second most pediatric common bone cancer (1,2). While patients with localized disease have a five-year survival rate of ~75%, this plummets to 20% for metastatic and recurrent disease. Immunothera... Read More

Development of T cell receptors targeting the common cancer antigen PRAME in pediatric malignancies

David Milewski, PhD, National Institutes of Health, National Cancer Institute
Recipient of the: $50,000 Spring for Sarcoma/Zach Cohen Memorial Research Award

Abstract: Antigen presentation is a universal process in which proteins in a cell are degraded into small fragments (peptides) and displayed on the cell surface for interrogation by the immune system. If a peptide is derived from an... Read More

Mechanisms of Arginine Starvation Induced Cell Death

Brian Van Tine, PhD, Washington University in St. Louis, MO
Recipient of the: $50,000 St. Louis Cure Sarcoma 6k Research Award

Abstract: PEGylated Arginine Deiminase (ADI-PEG20) is a therapeutic that degrades extracellular arginine.  In tumors like sarcoma that cannot make their own arginine due to a urea cycle defect, this agent put tumors into a starvati... Read More

Hippo pathway targeting in uterine leiomyosarcoma

Annalisa Astolfi, PhD, University of Ferrara
Recipient of the: $50,000 Dr. Richard and Valerie Aronsohn Memorial Research Award

Abstract: Leiomyosarcoma is the most common type of uterine sarcoma (uLMS), with an annual incidence of slightly less than two women per 100,000, characterized by a very poor response to standard therapies and an aggressive clinical... Read More

Genomewide therapeutic target screens in novel preclinical models of liposarcoma

Wantong Yao, PhD, The University of Texas MD Anderson Cancer Center
Recipient of the: $50,000 Jay Vernon Jackson Memorial Research Award

Abstract:  Liposarcoma is one of the most common soft-tissue sarcomas, with well-differentiated/dedifferentiated liposarcoma subtype forming the majority of cases. Although recurrences are frequent, surgery remains the mainstay of ... Read More